Who are Heparin Sodium In Plastic Container's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Taurolin, Revasc, Argatroban, Angiomax, Refludan, Renacidin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/heparin-sodium-12-500-units-in-dextrose-5-in-plastic-container.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Heparin Sodium In Plastic Container — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Heparin Sodium In Plastic Container (Heparin Sodium) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-coagulant.

marketed Anti-coagulant Antithrombin III, Factor Xa, Factor IIa Oligosaccharide Live · refreshed every 30 min

Target snapshot

Heparin Sodium In Plastic Container (Heparin Sodium) — Fresenius Kabi. Heparin enhances Antithrombin III's activity to inhibit coagulation factors Xa and IIa, preventing clot formation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Heparin Sodium In Plastic Container TARGET	Heparin Sodium	Fresenius Kabi	marketed	Anti-coagulant	Antithrombin III, Factor Xa, Factor IIa	1939-01-01
Taurolin	TAUROLIDINE		marketed	Anti-coagulant [EPC]		2023-01-01
Revasc	DESIRUDIN	Marathon Pharms Llc	marketed	Anti-coagulant	Prothrombin	2003-01-01
Argatroban	ARGATROBAN	Hikma Pharm Co Ltd	marketed	Anti-coagulant [EPC]	Prothrombin	2000-01-01
Angiomax	BIVALIRUDIN	Novartis	marketed	Anti-coagulant [EPC]	thrombin	2000-01-01
Refludan	LEPIRUDIN		marketed	Anti-coagulant	Prothrombin	1998-01-01
Renacidin	CITRIC ACID	Baxter	marketed	Anti-coagulant		1982-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-09-26 — Argatroban · 7687516 · Formulation · US
2027-09-26 — Argatroban · 7589106 · Formulation · US
2028-10-10 — Renacidin · 8450338 · US
2028-10-10 — Renacidin · 8481083 · US
2033-03-15 — Renacidin · 11439610 · US
2033-03-15 — Renacidin · 11337989 · US
2033-03-15 — Renacidin · 10568855 · US
2034-06-23 — Renacidin · 10624879 · US
2034-06-23 — Renacidin · 11191753 · US
2034-06-26 — Renacidin · 9827231 · US

Sponsor landscape (Anti-coagulant class)

· 1 drug in this class
Baxter · 1 drug in this class
Fresenius Kabi · 1 drug in this class
Marathon Pharms Llc · 1 drug in this class
Medicis · 1 drug in this class
Merck & Co. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Heparin Sodium In Plastic Container — Competitive Intelligence Brief. https://druglandscape.com/ci/heparin-sodium-12-500-units-in-dextrose-5-in-plastic-container. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab